Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies.
about
Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamicsVEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedsideTheranostic applications of antibodies in oncology.Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma.Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?Emerging trends for radioimmunotherapy in solid tumorsVEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors.Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors.Radionuclide imaging of drug delivery for patient selection in targeted therapy.Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model.Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.89Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89Zr Radiochemistry.Targeted therapy in first line treatment of RAS wild type colorectal cancer.Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts.Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.Dynamics of IGF-1R expression during endocrine breast cancer treatment.Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model.Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma.Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab.
P2860
Q26746067-96B4BC85-767B-4AF3-BE60-2C75260DD523Q26770678-2E037693-9D09-4973-9DA6-42C319C06C23Q27693293-64C30C86-F6D1-473F-8BDC-0D5FA04EF269Q30399006-F26CC88E-AAE9-4FE0-9548-2A0ED0B28FDAQ34538361-DD6E3AB7-2DEA-449E-8B1F-C8B022D86824Q34654670-F3A7EAC8-CABF-4BFA-8D27-F32553AC16D9Q36962594-7F17AC7E-E705-4089-8B93-C33FF3C80CD1Q37222795-FABBFC94-9419-4A4F-B52F-20B919ADD56FQ37587264-6262FAB9-0F9F-4234-8837-11723802A048Q37607383-A386D199-7DC7-4F78-96EA-7CD97813C99FQ38176652-7A931836-A381-441D-AD42-BA9E13A9A7ADQ38245841-FE646CD6-39B1-44B7-894B-64F58F01C66DQ39000880-686407FE-0B1A-4122-8E1C-C67E3D8846ACQ41690954-A76AA59D-0E99-43D6-B6A1-93D5FC472035Q43183749-89A74A39-24E8-490F-AB5C-E94161FDBC36Q47317142-AD7CF5EE-5712-4BF9-A89A-D4023E97B3D6Q50091855-9BAB904D-BB38-4D60-A3EC-05F0559F8134Q51752849-CA0E8017-9EE4-4256-9EE4-CFD236295AF6Q53071720-81ACCCE5-4B11-471F-882D-133B4D3DD5B8Q55286218-54A3E8EF-F85C-4B47-ADD8-4B564F942EE5Q55518414-EE2FAD01-C1C5-416A-A3AE-133FDEA2690C
P2860
Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Bevacizumab reduces tumor targ ...... factor 1 receptor antibodies.
@en
Bevacizumab reduces tumor targ ...... factor 1 receptor antibodies.
@nl
type
label
Bevacizumab reduces tumor targ ...... factor 1 receptor antibodies.
@en
Bevacizumab reduces tumor targ ...... factor 1 receptor antibodies.
@nl
prefLabel
Bevacizumab reduces tumor targ ...... factor 1 receptor antibodies.
@en
Bevacizumab reduces tumor targ ...... factor 1 receptor antibodies.
@nl
P2093
P2860
P921
P356
P1476
Bevacizumab reduces tumor targ ...... factor 1 receptor antibodies.
@en
P2093
Hanneke W M van Laarhoven
Janneke D M Molkenboer-Kuenen
Sandra Heskamp
Wim J G Oyen
Winette T A van der Graaf
P2860
P304
P356
10.1002/IJC.28046
P577
2013-02-15T00:00:00Z